8-K: Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement

Salarius Pharmaceuticals and Decoy Therapeutics have signed a definitive merger agreement to combine their businesses, leveraging Decoys peptide conjugate drug design platform.

Summary

• Salarius Pharmaceuticals and Decoy Therapeutics have agreed to merge, with the combined company to be named Decoy Therapeutics.
• The merger will leverage Decoys IMP3ACT platform, which uses machine learning and AI to design peptide conjugate therapeutics.
• Decoys pipeline focuses on respiratory infectious diseases and GI oncology.
• The combined company will also incorporate Salarius SP-3164 into peptide-based PROTACs.
• Salarius ongoing clinical trial of seclidemstat at MD Anderson will be supported while strategic alternatives are evaluated.
• Decoy has received approximately $7 million in non-dilutive funding from federal governments, corporations and The Bill & Melinda Gates Foundation.
• Decoy expects to file an IND for its lead asset, a pan-coronavirus antiviral, within the next 12 months.
• Decoy also plans to advance its broad-acting antiviral and GI cancer programs.
• The merger is structured as a stock-for-stock transaction, with Decoy investors expected to own approximately 86% of the combined company and Salarius stockholders approximately 14%, subject to adjustment and excluding any shares issued in a subsequent financing.
• The exchange ratio is based on a base value of $28.0 million for Decoy and $4.6 million for Salarius, subject to adjustments based on cash balances at closing.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the potential of the merger and Decoys technology. However, it also acknowledges the risks and challenges associated with the transaction and drug development.

Positives

• The merger combines Decoys innovative peptide conjugate platform with Salarius clinical development expertise.
• Decoys IMP3ACT platform has the potential to rapidly design new peptide conjugate drugs.
• The combined company will have a diversified pipeline targeting multiple therapeutic areas.
• Decoy has secured significant non-dilutive funding, reducing reliance on equity financing.
• The merger is expected to accelerate clinical development of Decoys pipeline.

Negatives

• The merger is subject to closing conditions, including a minimum $6 million financing.
• Salarius stockholders will experience significant dilution in the combined company.
• The combined company will need to raise additional capital to fund its operations.
• The combined company will need to obtain regulatory approvals for its product candidates.

Risks

• The merger is subject to closing conditions, including a minimum $6 million financing.
• The exchange ratio is subject to adjustment based on cash balances at closing.
• Salarius stockholders will experience significant dilution in the combined company.
• The combined company will need to raise additional capital to fund its operations.
• The combined company will need to obtain regulatory approvals for its product candidates.
• The combined company may not achieve the expected synergies from the merger.
• The combined company may face challenges in integrating the two businesses.
• The combined company may face competition from other biotechnology and pharmaceutical companies.

Future Outlook

The combined company expects to accelerate clinical development of novel peptide conjugate therapeutics for the treatment of respiratory viruses and cancer. Decoy expects to file an IND for its lead asset within the next 12 months and to advance its other programs.

Management Comments

• Rick Pierce stated that their team is excited to unlock significant shareholder value from their IMP3ACT platform.
• David Arthur stated that the proposed transaction with Decoy Therapeutics offers the best opportunity to create significant nearand long-term value.

Industry Context

The merger reflects a trend of combining innovative drug discovery platforms with clinical development expertise. Peptide conjugates are an emerging drug class with significant potential.

Comparison to Industry Standards

• The document mentions successful peptide conjugate drugs like Ozempic, Wegovy, Mounjaro and ZepBound, indicating Decoys technology is targeting a proven and growing market.
• The document also mentions antibody-drug conjugates (ADCs) as a comparable modality, highlighting Decoys potential to offer a more precise and cost-effective alternative.
• The document notes that Decoys manufacturing process is fully chemically synthetic, which is a departure from the complex and regulated biological processes required for antibody-based therapeutics, suggesting a potential cost advantage.

Management Changes

Corporate Governance

Stakeholder Impact

• Salarius stockholders will experience significant dilution in the combined company.
• Decoy stockholders will gain access to the public markets.
• Employees of both companies will be integrated into the new organization.
• Patients may benefit from the development of new therapies.

Next Steps

• Decoy expects to file an IND for its lead asset within the next 12 months.
• Decoy plans to advance its other programs, including a broad-acting antiviral and GI cancer program.
• The combined company will evaluate strategic alternatives for seclidemstat.
• The combined company will seek shareholder approval for the conversion of preferred stock to common stock.

Key Dates

Keywords

peptide conjugate, PROTACs, machine learning, artificial intelligence, respiratory viruses, oncology, drug development, biopharmaceutical, merger, clinical trials